Last $8.86 USD
Change Today +0.1003 / 1.14%
Volume 19.6K
CGIX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 1:58 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Open
$8.77
Previous Close
$8.76
Day High
$8.87
Day Low
$8.44
52 Week High
03/6/14 - $19.99
52 Week Low
12/3/14 - $4.83
Market Cap
86.2M
Average Volume 10 Days
81.9K
EPS TTM
$-1.53
Shares Outstanding
9.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutahine analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides FISH testing, an analysis of abnormalities at the chromosomal and gene levels; and flow cytometry testing, an immuno phenotype analysis of specific markers inside cells. Further, it offers histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various non-proprietary oncology-focused tests and laboratory services comprising molecular testing, sequencing mutational analysis, flow cytometry testing, histology testing, and cytology testing services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.

61 Employees
Last Reported Date: 03/28/14
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $649.0K
Vice President of Research & Development
Total Annual Compensation: $291.3K
Compensation as of Fiscal Year 2013.

cancer genetics inc (CGIX) Key Developments

Unique Genomic Panel Selects Cancer Genetics, Inc. for Focus::CLLTM to Use in Global Clinical Trial

Cancer Genetics, Inc. announced that its unique genomic panel for CLL, Focus::CLLTM, has been selected to provide genomic information for CLL patients in a global clinical trial. The trial is expected to assess several hundred patient specimens during 2015. Focus::CLLTM will be used to help guide patient stratification and management during the trial. The NGS-based panel is the only clinically validated, disease-focused genomic panel being offered in a commercial clinical setting for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Focus::CLLTM is approved for clinical use by the Clinical Laboratory Improvement Amendments (CLIA). The Focus::CLLTM panel assesses genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel [3] was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes. In addition to being available as an individual test, Focus::CLLTM has been integrated into the company's Complete TM offering for CLL/SLL.

Cancer Genetics, Inc. Presents at BTIG Medical Technology, Diagnostics and Healthcare IT Conference, Feb-18-2015

Cancer Genetics, Inc. Presents at BTIG Medical Technology, Diagnostics and Healthcare IT Conference, Feb-18-2015 . Venue: Cliff Lodge Snowbird Ski &Summer Resort, Snowbird, Utah, United States. Speakers: Panna Sharma, Chief Executive Officer, President and Director.

Cancer Genetics, Inc. Appoints Randy Goodman as Director of Reimbursement and Clinical Revenue Cycle Management

Cancer Genetics, Inc. announced the appointment of Randy Goodman, Ph.D., as director of reimbursement and clinical revenue cycle management. Goodman will be responsible for reimbursement, managed care, payer access and revenue cycle management. Prior to joining CGI, Goodman served as project director for health economics, reimbursement strategy, and health care policy at Precision for Medicine. From 2009 to 2011, Goodman served as senior director of global health economics and reimbursement strategy at ImpediMed, Inc. Prior to his time at ImpediMed, Goodman was the director of health economics, policy, and reimbursement for Access MediQuip, LLC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $8.86 USD +0.1003

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $35.15 USD -0.1545
Genomic Health Inc $30.95 USD -0.15
NeoGenomics Inc $4.61 USD +0.055
Response Genetics Inc $0.55 USD -0.019
Rosetta Genomics Ltd $3.38 USD -0.09
View Industry Companies
 

Industry Analysis

CGIX

Industry Average

Valuation CGIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit www.cancergenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.